Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database
- U A Walker1,
- A Tyndall1,
- L Czirják2,
- C P Denton3,
- D Farge-Bancel4,
- O Kowal-Bielecka5,
- U Müller-Ladner6,
- M Matucci-Cerinic7,
- and the EUSTAR co-authors
- 1Felix Platter Spital, Basel, Switzerland
- 2University of Pecs, Pecs, Hungary
- 3Royal Free Hospital, London, UK
- 4Hopital Saint-Louis, Paris, France
- 5Medical University of Bialystok, Bialystok, Poland
- 6Justus-Liebig-University, Giessen, Germany
- 7University of Florence, Florence, Italy
- Dr U A Walker, Basle University Department of Rheumatology, Felix Platter Spital, Burgfelderstrasse 101, Basel 4012, Switzerland; ulrich.walker{at}fps-basel.ch
- Accepted 20 June 2008
- Published Online First 14 July 2008
Abstract
Background: Systemic sclerosis (SSc) is a vasculopathy with increased tissue deposition of collagen. The aetiology is unknown. Genetic and environmental susceptibility factors have been implicated. It is unknown whether disease presentation varies within Europe.
Aims and Methods: The baseline data of all SSc patients entered in the EULAR Scleroderma Trials and Research (EUSTAR) database up to April 2007 were analysed for geographical differences with regard to organ involvement, and geographical clusters with regard to clinical subsets (diffuse vs limited SSc) and autoantibodies (anticentromere vs anti-Scl70).
Results: 3661 patients from 79 centres in 62 cities and 23 countries were analysed. There was no clear trend between geographical coordinates and SSc subsets, although there appeared to be an increased prevalence of Scl70 in the more eastern centres. There was no association between geographical longitude or latitude and the age at the onset of Raynaud’s phenomenon or the onset of non-Raynaud’s symptoms. There was also a trend for the more eastern centres to care for patients with a higher prevalence of more severe organ manifestations (pulmonary arterial hypertension, cardiac involvement). Between different centres within one city there was a large variability in the frequency of organ complications.
Conclusion: This analysis suggests that eastern centres care for more severe SSc manifestations in Europe. Large differences in patient referral account for a large local variability of SSc presentations and preclude the identification of genetic or environmental factors.
Footnotes
-
Competing interests: None.
-
Funding: EUSTAR is supported by a research grant from EULAR and is under the auspices of the Standing Committee for International Studies including Clinical Trials (ESCISIT).
-
Ethics approval: Ethics approval was obtained.
-
Patient consent: Obtained.
-
‣ The appendix is published online only at http://ard.bmj.com/content/vol68/issue6








